Your browser doesn't support javascript.
loading
Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications.
Armideo, Erin; Callahan, Colleen; Madonia, Lara.
Afiliación
  • Armideo E; The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Callahan C; The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Madonia L; The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
J Adv Pract Oncol ; 8(1): 44-55, 2017.
Article en En | MEDLINE | ID: mdl-29900016
Despite more intensive therapy, high-risk neuroblastoma continues to be a challenging disease to treat. Postconsolidation immunotherapy has been studied for many years and has proven to be effective in clinical trials. Immunotherapy has become the standard of care for patients with high-risk disease, and many institutions across the country are providing this therapy. The care of these patients is complex and often associated with many side effects. The purpose of this article is to review the most common side effects seen in clinical practice and examine their management. Furthermore, this article will discuss the need for a consistent and educated multidisciplinary front-line team to care for these patients, with advanced practitioners playing a lead role to provide the care and attention needed for this patient population.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Risk_factors_studies Idioma: En Revista: J Adv Pract Oncol Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Risk_factors_studies Idioma: En Revista: J Adv Pract Oncol Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos